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Abstract
Noroviruses are the leading cause of acute gastroenteritis in the United States and are responsible for at least 50 %
of acute gastroenteritis outbreaks occurring worldwide each year. In addition, noroviruses have caused outbreaks
on cruise ships, in nursing homes and hospitals, and in deployed military personnel, but its role in the etiology of
travelers’ diarrhea is not well defined. The aim of this review is to describe the role of noroviruses in travelers’
diarrhea in terms of epidemiology, current diagnostics, treatment and vaccine development efforts. Studies have
shown prevalence rates of noroviruses in travelers’ diarrhea cases ranging from 10–65 %. It is likely that norovirus
prevalence rates are highly underestimated in travelers’ diarrhea due to rapid onset, short duration of the illness,
limited availability of laboratory facilities, and the fact that most clinical laboratories lack the diagnostic capability to
detect noroviruses in stool. Further, additional studies are needed to accurately determine the true prevalence rates
of norovirus as an etiologic agent of diarrhea among travelers to different regions around the world. With the rapid
progress in the development of a norovirus vaccine, travelers could serve as an ideal population for future
norovirus clinical trials.
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Background
Travelers’ Diarrhea (TD) is the most common illness re-
ported in international travelers from industrialized na-
tions to low-income, developing nations [1, 2]. TD can
be caused by multiple etiologic agents to include enteric
bacteria (diarrheagenic Escherichia coli, Shigella spp.,
Campylobacter spp.), viruses (noroviruses, adenoviruses,
astroviruses) and parasites (Giardia lamblia, Entamoeba
histolytica, Cryptosporidium parvum) [3, 4]. However,
noroviruses (NoVs) are the number one cause of epi-
demic gastroenteritis characterized by vomiting and
diarrhea and are responsible for at least 50 % of all acute
gastroenteritis outbreaks worldwide [5, 6]. Though NoV
has been associated with several global epidemics, the
prevalence of NoV-associated TD is not well defined
and the number of studies aiming to assess NoV as a
primary etiologic agent responsible for TD has been lim-
ited [7, 8]. There have been many excellent reviews re-
cently published on the epidemiology and impact of
NoVs [8, 9] and we refer the reader to these reviews for
their completeness, whereas in this article we will focus
on what is known about the role of NoV in travelers and
how this information can be used for pre-trip travel
medicine consultations, diagnosis of NoV in acute
gastroenteritis (AGE) cases from returning travelers, and
future goals of prevention through vaccines and other
preventative interventions.
Epidemiology of norovirus: implications for travelers
NoVs are a large family of evolutionarily divergent vi-
ruses named after the prototype Norwalk virus discov-
ered in Norwalk, Ohio in 1968 [9] and have emerged
since their discovery as one of the leading causes of
AGE in all populations, including travelers. The viral
capsid is composed of two proteins, VP1 and VP2. VP1,
which self-assembles when expressed in various cell cul-
ture models, is the primary antigen utilized in serological
diagnostic assays [5, 10]. VP1 is also important in bind-
ing to host cells via the interaction of the protruding (P)
domain with histo-blood group antigens (HBGA) and
the P domain also undergoes both antigenic drift and
shift that allows both immune evasion and give NoVs
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their pandemic potential [11]. VP2 appears to bind to
VP1, possibly stabilizing the capsid especially when ex-
posed to harsh environments.
NoVs exhibit considerable genetic diversity and are
categorized into seven known genotypes (GI-GVII), of
which GI, GII, and GIV have been found to cause dis-
ease in humans [9, 12]. GII is the most common NoV
found in human gastroenteritis cases, encompassing ap-
proximately 85 % of cases where the remaining 15 % of
identified NoV infections are caused by GI with only
sporadic cases due to GIV. NoVs are further categorized
into genotypic subtypes based on the sequence of the
viral capsid protein gene for VP1 [9, 12]. Of the GII vi-
ruses, the most common genotypic subtype is GII.4
which has been circulating worldwide since the 1990s.
Continuing viral evolution has led to the emergence of
novel pandemic strains every two to three years that
have been responsible for many outbreaks and replaced
endemic NoV variants [12]. Since its emergence in 2012,
the GII.4 Sydney variant is the predominant GII.4 sub-
type in circulation [12].
It is estimated that NoVs account for 23 million cases of
AGE each year in the United States alone and many more
in developing regions where sanitation and hygiene prac-
tices are less robust. While the majority of cases result in
only mild infections, approximately 500–700 cases in the
U.S. per year are severe enough to lead to death [13]. In the
U.S., individuals older ≥ 65 years old were most at risk for
death from NoV infection while children < 5 years was the
predominant age group for those individuals requiring
medical attention [13]. People at risk for NoV infection in-
clude those living in close quarter facilities such as nursing
homes and cruise ships, living conditions where food sani-
tation/hygiene practices are unsanitary and those individ-
uals with an impaired immune system [9]. NoVs, which
have a low infectious dose of an estimated 100 virions, are
highly transmissible via the fecal-oral route [9, 14]. How-
ever, due to the low infectious dose and common symp-
toms of both vomiting and diarrhea, there have been
suggestions that transmission can also occur via aerosolized
vomitus or fecal matter [15]. Due to its ability to resist des-
iccation and disinfection, NoV is able to survive for long
periods on surfaces allowing for transmission via fomites.
These characteristics give NoV the propensity to cause sec-
ondary infections leading to its high potential to cause out-
breaks of AGE in closed group settings. Many studies have
examined NoV transmission in hospital settings, long-term
care facilities, schools, and military camps, but less is
known about the role of NoV in travelers. With the in-
creasing rates of leisure travel especially to developing re-
gions of the world, TD is a frequently encountered concern
for travelers. Additionally, politicians, diplomats, and mili-
tary personnel frequently travel to regions of high-risk for
TD and prevention of illness is important for mission
accomplishment. Given the possible association between
NoV acute infection and the subsequent development of
post-infectious diarrhea sequelae such as irritable bowel
syndrome (IBS), avoiding infection may be important for
long term health [1].
There are several studies that have shed light on the
role of NoV in TD among travelers. In a study of 3 dif-
ferent cohorts of U.S. European travelers (84.2 % male,
mean age 28.8 years) to Guatemala, Mexico or India,
NoV during various periods between 2002–2007, in
combination was detected in 10.2 % of moderate to se-
vere diarrhea cases (at least 3 or more unformed stools
and other symptoms) and was the second most common
pathogen detected following diarrheagenic E. coli (ETEC
and EAEC) [16]. Prevalence of NoV in this study varied
from 3–17 % among the different regions (3–12 % from
Mexico, 11.9 % from India, and 17 % from Guatemala) with
many travelers found to have co-infections with bacterial
and parasitic pathogens and 22.4 % infected with 3 or more
pathogens [16] In another study of European travelers
(52.9 % male, mean age 37 years) returning to Germany
from over 50 worldwide locations, NoV was found in
15.7 % (9/57), persons with diarrhea and 1/47 asymptom-
atic persons [17]. Additionally, backpacking trips had the
highest association with NoV infection (OR =4.9), followed
by business trips (OR = 1.4), and packaged vacations with
the lowest association (OR = 0.3) [17]. The study by Apelt,
et al. [17] demonstrated that of the 9 NoV cases detected,
onset of symptoms ranged from 10 days prior to return to
up to 4 days after returning, suggesting that testing patients
as much as a week after the onset of diarrhea, espe-
cially if experiencing continuing symptoms, is a worth-
while strategy. Other studies of travelers to various regions
around the world have shown NoV prevalence ranging
from 15–65 % with varying genotypes detected [5, 17–22].
Additionally, NoV has been a well-documented cause of
outbreaks on cruise ships and transmission has been ob-
served during air travel [9, 15, 23]. TD has been tradition-
ally thought to be caused by bacterial pathogens [24], but
with the association of NoV among many different food
types and water sources [24, 25]; the risk of exposure to
NoV in travelers is high and should be considered in all
cases of TD. Finally, since NoV has been shown to be shed
in stools for as much as 56 days after symptoms have re-
solved, enhanced awareness of sanitation and hygiene
among returning travelers who experienced TD is neces-
sary to avoid secondary cases among contacts.
Symptoms and clinical outcomes
The clinical course of NoV infection has been described
in detail in many reviews [1, 9], but summarized here as
it relates to disease in travelers who are usually relatively
healthy and not commonly among the extreme age
groups (young and old) that may be more vulnerable to
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infection and complications. In healthy adults, infection
by NoV is typically acute and self-limiting, but causes
significant morbidity that arises from a combination of
symptoms including the classic symptoms of vomiting
and diarrhea as well as accompanying symptoms such as
abdominal cramping, fever, and malaise. Symptoms typ-
ically emerge between several hours and two days post-
infection and resolve within 72 h of presentation [26].
Of 23 confirmed NoV-attributable cases reported in U.S.
students who traveled to Mexico between 2007 and 2008,
the recorded symptoms included abdominal cramping,
vomiting, and severe levels of nausea and fecal urgency
[16]. Similarly, abdominal cramping (95 %), nausea (74 %),
and fecal urgency (63 %) were experienced in a majority of
the NoV-confirmed cases in a separate study on U.S. and
European travelers returning from Guatemala, India, and
Mexico [26]. Descriptions of NoV-attributable gastroenter-
itis among deployed military personnel have also reported
similar symptoms. A 2002 NoV outbreak of >1,300 British
military personnel in Iraq cited high levels of diarrhea
(89 %), abdominal pain (85 %), nausea (80 %), and vomit-
ing (56 %), with an average hospitalization of 1.6 days [27].
Another NoV outbreak among U.S. military personnel in
Turkey involved multiple genotypes and showed a similar
pattern with 79 % of individuals having diarrhea, 77 % ab-
dominal cramping, 63 % nausea, and 46 % vomiting [28].
While infection typically results in mild to moderate
symptoms of short duration, a more prolonged and severe
clinical course has been described in infants, the elderly,
and among immunocompromised individuals [26, 29, 30].
Beyond the acute illness itself, NoV has also been associ-
ated with an increased risk of post-infectious sequelae.
Diagnostic surveys returned after a waterborne outbreak
in Italy in 2009 indicated that 40/348 diarrhea cases (12 %)
went on to develop IBS. At 12 months post-infection, the
odds of developing IBS was >10-fold higher in the exposed
group as compared to unexposed controls [31]. At the
same time, a large retrospective cohort study spanning
eight years that involved 1,718 cases of NoV infection esti-
mated an increased risk of dyspepsia, constipation, and
gastroesophageal reflux disease (GERD) following infec-
tion [32]. Compared to unexposed controls, increased rela-
tive risk (RR) was noted for dyspepsia (RR = 1.44; 95 % CI:
0.84–2.47), constipation (RR = 1.32; 95 % CI: 0.96–1.81),
and GERD (RR = 1.39; 95 % CI: 1.07–1.81), in the exposed
outbreak population. Interestingly, in contrast to the afore-
mentioned IBS studies, this same study found a decreased
risk for IBS among infected individuals rather than an in-
creased risk for development of IBS (RR = 0.68; 95 % CI:
0.30–1.51) [32]. Other reports have also hinted at possible
connections between infection and the development of re-
active arthritis [33] and exacerbations of inflammatory
bowel diseases (IBD), although this has been debated in
other reports [34, 35].
Epidemiologic evidence in favor of an association be-
tween NoV infection and the development of post-
infectious conditions has been accumulating slowly over
the past decade, and the supporting data are congruent
with studies linking bacterial causes of gastrointestinal
illness to chronic sequelae [36, 37]. However, further
studies are needed to establish a causal link. Elucidating
the relationship between NoV and the development of
any associated sequelae will require well-designed pro-
spective studies that examine the strength of the associ-
ation, any temporal and dose–response relationships
that may exist, and the consistency of the effect of NoV
infection on the postulated outcome. At the same time,
these studies should take into account host factors that
may determine the relative risks of different populations,
including travel populations, and any potential differen-
tial influence that disparate genogroups and strains of
NoV may have on a particular outcome.
Diagnostics and testing strategies
Understanding the biology, transmission, and epidemi-
ology of NoV has been limited by a lack of reliable and
cost-effective diagnostics. Much of the struggle to under-
stand the biology and burden of NoV is due to the in-
ability to culture the virus [12] with some studies
resorting to the use of surrogate viruses (feline or mur-
ine calciviruses) to assess virus viability after treatment
with disinfectants. Lack of culture capability limits inves-
tigation into the biology and pathogenesis of NoV and
also prevents large scale amplification to create pure
viral stocks used for internal controls in laboratory tests,
thus NoV must be stored in frozen stools. A recent
breakthrough by Jones et al. allowing for culture of NoV
in B cell lines with the addition of HBGA-bearing bac-
teria may have significant impact for future NoV diag-
nostics [38, 39], but is not available in most clinical
laboratories. Thus other methods for detection are com-
monly used including enzyme-linked immunosorbant
assays (ELISA) for NoV antigen detection or reverse-
transcription polymerase chain reaction (RT-PCR) to de-
tect specific NoV genes. For these assays, the preferred
specimen is fresh or frozen stool. Vomitus can also be
tested if collected and processed immediately. Testing of
food and environmental surfaces is also possible, but low
numbers of viral particles and potential inhibitors may
affect the sensitivity of detection.
Recently, there have been excellent reviews of the per-
formance of both commercial and laboratory developed
ELISAs and RT-PCR assays for detection of NoV and we
refer the reader to these sources for a complete descrip-
tion of the performance of available assays [9, 12]. As dis-
cussed in these reviews, the performance of ELISAs a for
antigen detection is limited by sensitivity based on viral
load and ability to detect different genotypic subtypes.
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Therefore a recommendation is to test multiple stools to
increase sensitivity, a strategy often employed during
outbreak situations where a few positive samples are suffi-
cient for source attribution [9, 12].
Because of the poor sensitivity of NoV antigen detec-
tion by ELISA, molecular detection of NoV has become
the preferred method. Most RT-PCR assays use primers
that target the conserved region between ORFs 1 and 2
with good sensitivity and specificity [9, 12]. Although
RT-PCR assays require technical expertise of laboratory
staff and are expensive, they are becoming increasingly
cost-effective as more commercialized assays become
available. New multiplex molecular assays targeting the
common causes of infectious enteric diseases including
NoV have been developed including three FDA-approved
multiplex assays (Biofire FilmArray Gastrointestinal Panel,
Luminex Gastrointestinal Pathogen Panel, and Nano-
sphere Verigene Enteric Pathogens Test) [9, 12]. The ad-
vantage of the multiplex assays is detection of multiple
pathogens (7–23 depending on the assay chosen) which
can improve overall detection of causative etiology, espe-
cially with viruses [40]. Adding molecular detection for
NoV and other enteric viruses is beneficial considering be-
tween 40–60 % of samples submitted to laboratories do
not yield an identified pathogen for a variety of reasons in-
cluding sample collection procedures, transport time, and
low pathogen levels [41]. As multiplex molecular testing
becomes more commonplace in diagnostic laboratories, a
more complete understanding of the complex etiology of
TD will be determined. Many studies have reported co-
infections when using multiplex methods with NoV often
found with other enteropathogens raising questions about
how these complex interactions affect disease duration,
severity, and post-infectious outcomes.
With improvements in the costs, ease of use, and avail-
ability of molecular testing in diagnostic laboratories, cli-
nicians should be encouraged to submit samples for
testing from returning travelers with current symptoms of
AGE and also those reporting disease in the previous
week. NoV should be considered in the differential diag-
nosis of all returning travelers and tests for NoV should be
requested in addition to standard stool culture. This is im-
portant not only for treatment of the individual patient,
but in cases which are found positive for NoV, the results
would allow guidance on continued focus on hygiene and
proper disinfection to avoid spread among cohabitants of
infected travelers since NoV can be shed in stools for a
long duration after symptoms resolve [9]. Similarly, NoV
should be the primary consideration of all persons with
AGE reporting contact with a recent returning traveler.
Treatment and prevention
Between 12 % and 46 % of travelers are forced to alter
their travel plans because of acute diarrheal infections
[1]. However, efforts to develop targeted therapeutics for
NoV infections have long been stagnated by the lack of
appropriate small animal models and the infeasibility of
propagating NoV in cell culture [42]. While NoV treat-
ment options have largely centered on supportive care
[9, 26], there is some impetus for broadening treatment
options even among the healthy adult population. In the
sense that they have critical or itinerant activities that
necessitate rapid relief of the discomfort of acute diar-
rhea, some travelers may be grouped alongside emer-
gency workers, military service members, and other
priority groups. The particularly high transmissibility of
NoV also increases pressure to identify drugs that can
mitigate its outbreak potential. Otherwise healthy trav-
elers suspected of suffering from NoV-caused diarrhea
are generally given oral rehydration therapies and bis-
muth subsalicylate (Pepto-Bismol) [9, 16]. Anti-motility
agents such as loperamide and diphenoxylate plus atro-
pine may also be included in the limited arsenal of non-
antibiotic treatment options for viral gastroenteritis, al-
though caution must be exercised in instances where co-
infections with enteroinvasive dysenteric pathogens are
suspected [43]. However, in several studies involving
both children and adults, subjects with gastroenteritis
who received loperamide versus placebo reported no sig-
nificant difference in the incidence of adverse effects in
either treatment arm [44].
In instances where oral rehydration efforts have failed
and the subject runs the risk of dehydration, antiemetic
drugs (commonly used to prevent nausea in patients
undergoing chemotherapy) have also been evaluated as
both a treatment of AGE and as a transmission control
measure in pediatric populations [44–46]. In one such
treatment trial involving ondansetron, less than half of the
children receiving oral ondansetron required intravenous
hydration compared to the placebo control group [47].
Measures to control vomiting may also be important in
controlling person-to-person transmission of NoV among
travelers, particularly in the classic setting of a cruise ship
outbreak [48, 49].
Among the few targeted, virus-specific approaches
against NoV infection under investigation is nitazoxa-
nide, a compound licensed in the US for the treatment
of cryptosporidiosis but with broad-spectrum activity
against a number of protozoal and helminthic parasites
and bacteria [50]. A phase II treatment trial involving
children with severe rotavirus AGE found the duration
of diarrheal illness in children reduced by over two-fold
relative to a placebo-controlled cohort [51]. A clinical
trial of nitazoxanide efficacy in thirteen NoV-confirmed
cases of AGE showed a significantly shortened time to
resolution of symptoms (1.5 days versus 2.5 days) in sub-
jects who received 500 mg of nitazoxanide for three days
compared to a placebo group [52]. Having been licensed
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as an anti-parasitic compound for nearly 15 years, an es-
timated 75 million Americans have been exposed to
nitazoxanide without any serious adverse effects re-
ported [53, 54] and, in part due to its broad-spectrum
applications, the drug is now being considered as an es-
sential medicine for neglected tropical diseases [55]. Fur-
ther data from clinical trials involving nitazoxanide
including a comparison to loperamide for efficacy may
provide clinicians travelers with a future treatment op-
tion for NoV infections acquired during travel.
Due to the highly infectious nature of NoV and rapid
impact on functionality, all travelers should be counseled
during their pre-travel consultations on diligence of
hand hygiene prior to eating, use of bottled water at all
times including when brushing teeth, and reducing close
contact with persons experiencing symptoms of AGE.
Additional discussions should include an evaluation of
the type of travel (adventure/backpacking, business, etc.)
and elaboration of the level of risk associated with the
traveler’s plans and potential prevention strategies. Fur-
thermore, advice to the traveler, as with any cause of
diarrhea proper hydration that includes electrolytes of
equivalent volume to that lost through diarrhea and
vomiting is the best treatment during the duration of
symptoms. Travelers should also be encouraged on sani-
tation and hygiene discipline when sick to avoid spread-
ing among their group and to other travelers.
Vaccine
The development of a safe efficacious vaccine to protect
both travelers and non-travelers against NoV is consid-
ered one of the most feasible and economical ap-
proaches to limiting the potential impact of NoV
infections. Currently there are no approved vaccines di-
rected against NoV and development of a vaccine has
been hampered by several challenges highlighted below.
With the current inability to culture NoV and develop at-
tenuated vaccine strains in the laboratory setting, vaccine
efforts have instead focused on the development of other
platforms. Jiang, et al. reported in 1992 that the VP1 protein
of NoV, when expressed in cell culture, is able to
self-assemble into virus-like particles (VLPs) [56].
With structural and antigenic properties similar to native
virus but in a noninfectious, non-replicating form, these
VLPs were identified as potential vaccine candidates and
many studies have been conducted over the last 10 years
showing good serum responses and initial efficacy, provid-
ing the foundation for recent promising studies.
In an effort to develop a VLP-based vaccine with broad
coverage against circulating NoVs of both the GI.1 and
GII.4 genotypes, Treanor, et al. conducted testing on a
bivalent GI.1- GII.4 consensus VLP vaccine delivered by
the intramuscular route. Subjects were given 5, 15, 50 or
150 μg of each VLP vaccine 28 days apart. Initial safety
and immunogenicity studies indicated the vaccine was
well tolerated and a robust immune response was stimu-
lated with 100 % of subjects responding to GI.4 VLP
vaccine at any dose level and 56–88 % responding in a
dose dependent manner to GII.4 consensus VLP [57].
The vaccine stimulated a strong serum antibody and
antibody-secreting cell (ASC) response following one
dose. However, the early robust ASC response is indica-
tive of a recall response by memory B cells as opposed
to a naïve immune response [58]. This finding is not sur-
prising given the high likelihood that the human volun-
teers had previously been exposed to NoV through
natural infection. While the vaccine stimulated a robust
immune response in what are presumably previously ex-
posed subjects, how the vaccine would perform in naïve
individuals remains to be assessed.
As a follow on to the previous trial, a second study by
Bernstein, et al. utilized a bivalent vaccine composed of
50 μg of GI.1 VLPs and 50 μg of consensus GII.4 VLPs
with monophosphoryl lipid A (MPL) and alum adjuvants
[59]. Two intramuscular injections were given 28 days
apart. Patient immune responses were monitored and
subjects were challenged with GII.4 NoV at a minimum
of 28 days following the second vaccination. No severe
adverse events were recorded as a result of vaccination.
Twenty eight days following the first vaccination sub-
jects exhibited a 62.2-fold increase in ELISA geometric
mean titers (GMTs) to GI.1 and a 10.8-fold rise in
ELISA GMT to GII.4. However, no significant increase
in antibody titers was detected following the second
dose. One hundred percent of vaccinated subjects dem-
onstrated a seroresponse against GI.1, whereas the seror-
esponse to GII.4 peaked at 89.8 % as compared to only
2.1 % of subjects given placebo injections demonstrated
a seroresponse [59]. Despite the promising immuno-
logical response, the vaccine did not significantly reduce
the incidence of protocol-defined illness of gastroenter-
itis, possibly due to an overly strict definition combined
with under self reporting of symptoms. However, vacci-
nated subjects did demonstrate a reduction in self-
reported severe, moderate or greater, and mild or greater
severity of vomiting and/or diarrhea [59]. Taken together
these data may indicate that a NoV vaccine may provide
better protection against severe manifestations of the
disease rather than moderate or milder infections, not
unlike the results seen with the rotavirus vaccine.
The economic feasibility for the development of a
NoV vaccine is comparable to many current vaccines in
that long lasting protection with high efficacy is required
to offset vaccination costs. When vaccine cost effective-
ness was modeled based on the estimated US NoV bur-
den, it was determined that a vaccine that provided only
12 months of protection would not result in cost sav-
ings; however, if the vaccine protected for at least
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48 months (≥50 % efficacy/≤$25 or ≥75 %/≤$50), the
overall healthcare costs savings would be $100 million to
$2.1 billion a year [60]. In the U.S. military, itself a
unique travel population, NoV has been a major cause
of duty days lost due to AGE in deployed operations.
Using the parameters outlined in their model, Tallant et
al. estimated that a NoV vaccine would cost $1344 per
duty day lost averted (e.g. subject able to perform duties
versus being ill). However, the authors state that the
monthly incidence and pathogen prevalence for NoV are
most likely under-reported and when the model was ad-
justed to include illness with vomiting, the cost per duty
day lost averted dropped to $572, which is fiscally favor-
able when compared to the U.S. military operational
costs estimate of $935 per day per deployed troop. Add-
itionally, the authors indicate that a NoV vaccine would
enhance troop safety and well-being as distractions due
to gastrointestinal illness in deployed settings would be
minimized [61]. Clearly, a long lasting, efficacious vaccine
directed against NoV would be able to provide significant
domestic healthcare savings and also provide a beneficial
cost benefit ratio for operations in deployed conditions
where gastrointestinal illness can jeopardize the mission.
An efficacious vaccine would benefit travelers as the likeli-
hood of significant NoV outbreaks occurring particularly
on cruise ships would be greatly reduced and a NoV vac-
cine could eventually become part of a traveler’s clinician
recommendations for travelers.
Conclusions
NoV will continue to remain a pathogen of critical im-
portance as a major cause of AGE worldwide. With NoV
incidence in travelers being likely underestimated due to
challenges in NoV diagnostics, improvement in molecu-
lar methods for identification NoV will enable future TD
studies to adequately measure NoV as a burden of AGE
and also allow for a better clinical diagnosis of NoV in a
hospital setting. Future studies aimed at further charac-
terizing the epidemiology of NoV in Western travelers
should be undertaken as travelers could prove to be a vi-
able population for future NoV vaccine trials.
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